Esketamine Effective and Costly Treating Treatment-Resistant Depression

Mclean Hospital

HCP Live

Dr. Eric L. Ross and collaborators examine the cost-effectiveness of esketamine, a novel intranasally dosed antidepressant for patients with treatment-resistant depression.

Read Full Article

Topics

Depression Ketamine

McLean Main Navigation

In the Media: Esketamine Effective and Costly Treating Treatment-Resistant Depression

HCP Live

McLean Hospital’s Anti-Racist, Justice, and Health Equity Action Plan

Pushing Back Against Feelings of Loneliness

Staying Centered in Turbulent Times

Tailoring Psychotherapy for Borderline Personality Disorder

In the Media: Esketamine Effective and Costly Treating Treatment-Resistant Depression

HCP Live

You May Also Like

What Causes Depression? What You Believe Matters

ECT Shouldn’t Be a Last-Resort Treatment

Ketamine for Depression Still Too Expensive for Widespread Use

The Benefits of Taking a Mental Health Day

Resources

Latest Videos

McLean Hospital’s Anti-Racist, Justice, and Health Equity Action Plan

Pushing Back Against Feelings of Loneliness

Staying Centered in Turbulent Times

Tailoring Psychotherapy for Borderline Personality Disorder

Keep Up With McLean!